<DOC>
	<DOCNO>NCT00461058</DOCNO>
	<brief_summary>This 2 arm study compare safety , tolerability efficacy aleglitazar Actos patient type 2 diabetes symptomatic NYHA class II heart failure . Eligible patient randomize receive either aleglitazar , titrate individual maximum tolerate dose 0.3mg p.o . daily , Actos , titrate individual maximum tolerate dose 45mg p.o . daily , addition prescribe diabetes therapy applicable . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Comparative Study Aleglitazar Actos Patients With Type 2 Diabetes Mellitus New York Heart Association ( NYHA ) Class II Heart Failure .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; type 2 diabetes &gt; =1 month ; drug naive , receive stable dos &lt; =2 oral antihyperglycemic medication ; HbA1c 6.510.0 % screening ; symptomatic , stable NYHA class 2 heart failure screen . type 1 diabetes ; current previous treatment insulin ; uncontrolled hypertension ; NYHA class 1 , 3 4 screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>